Lilly USA Updates Health Education Program to Help Patients with Depression Build Network of Support

Eli Lilly and CompanyThe Support Partners Program offered by Lilly USA shows individuals with depression ways to build their own support group, which, in turn, can help them better deal with their depression symptoms. The Support Partners Program can also help people better understand the illness and the importance of seeking help from a health care professional.

Available at SupportPartnersProgram.com, all materials are available in both English and Spanish and address a variety of topics related to depression, including a step-by-step guide that may help with the possibility of getting better.

"Lilly is proud to introduce its updated Support Partners Program as part of our extensive health education offerings," said Alex M. Azar II, vice president, Lilly USA. "We believe it is vital that we work together with patients and others in the health care system to improve patient care and overall public health. Providing these resources for patients is just one of our many initiatives."

Program components in the Support Partners Kit include: Managing Your Depression, which provides helpful tips, tools and steps to follow on building a support group and managing symptoms; Being a Support Partner, which includes information for the selected partner on everyday steps to help their friend or loved one with depression; Shared Guidebook, which features information designed for the patient and his or her Support Partner to focus on setting goals, tracking progress and noting important information; Ages and Stages, which outlines how women's experiences with depression can change during their lives; Canine Companions, which offers information about how dogs can have a positive effect on the overall health and emotional well-being of patients with depression.

In addition to Support Partners, Lilly offers a number of other educational materials online at lillyforbetterhealth.com. A few of these include:

  • A Healthy You! - America's Guide to Healthy Living is a 148-page book that brings together a wide variety of health information from reliable sources in a simple, easy-to-use format. What makes the book unique is an extensive list of resources available to the public in each state. These state-specific resources help connect people to health programs and agencies in their area, making the search for health information easier. The book is available in English and Spanish.
  • F.A.C.E. Diabetes Campaign is a grassroots movement focused on targeting African-Americans to help individuals and families overcome key barriers to success in living with diabetes.
  • Healthy Family Home is a national program designed to help families make moderate changes in how they eat, play and spend time together. The program encourages families to choose healthy goals that make sense for them and that lead to sustained improvements. Materials are in English and Spanish.
  • Lilly's patient assistance programs provide access to medications for patients in need. Over the past three years, Lilly has assisted more than 510,000 patients in the United States and distributed medications, valued at over $765 million.

About Eli Lilly and Company
Eli Lilly and Company, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. For additional information on Health Education Answers or Lilly's other patient care and disease management programs, visit www.lillyforbetterhealth.com.

Most Popular Now

Sanofi and GSK sign agreements with the Government…

Sanofi and GSK have signed agreements with the Government of Canada for the supply of up to 72 million doses of an adjuvanted COVID-19 vaccine, beginning in 2021. Thom...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

Scientists trace severe COVID-19 to faulty genes a…

More than 10 percent of young and healthy people who develop severe COVID-19 have misguided antibodies that attack not the virus, but the immune system itself, new resear...

Johns Hopkins researchers publish COVID-19 'predic…

Using a combination of demographic and clinical data gathered from seven weeks of COVID-19 patient care early in the coronavirus pandemic, Johns Hopkins researchers today...

Researchers uncover early results about an existin…

While scientists race to develop and test a vaccine effective against SARS-CoV-2, the virus that causes COVID-19, recent studies have indicated that countries with widesp...

Web resources bring new insight into COVID-19

Researchers around the world are a step closer to a better understanding of the intricacies of COVID-19 thanks to two new web resources developed by investigators at Bayl...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Boost for global response to COVID-19 as economies…

64 higher income economies have joined the COVAX Facility, a global initiative that brings together governments and manufacturers to ensure eventual COVID-19 vaccines rea...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

Adequate levels of vitamin D reduces complications…

Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a signif...